Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03780244 · ClinicalTrials.gov registry record · NA

Safety and Effectiveness of Sculptra Aesthetic for Correction of Nasolabial Folds.

A NA study, sponsored by Galderma R&D.

Completed
Registry status
NA
Development phase
80
Enrollment target

NCT03780244: Completed NA study, sponsored by Galderma R&D.

NCT03780244 is a NA study that has completed, run by Galderma R&D. The registered enrollment target is 80 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03780244, a NA study, has completed, sponsored by Galderma R&D.

COMPLETED
Registry status
NA
Development phase
80 participants
Enrollment target

Study Summary

This study has been designed to evaluate the safety of Sculptra Aesthetic as a single regimen for correction of Nasolabial Fold (NLF) contour deficiencies after changes in reconstitution and injection procedures compared to the approved label.

Primary Outcome

The WAS is a validated photograph-based outcome instrument that is designed specifically for quantifying facial folds. Scoring of NLF wrinkle severity (grades 0-5, with 0 representing no wrinkles and 5 representing very deep wrinkles, redundant fold) was based on visual live assessment by the Blinded Evaluator at defined timepoints and not on a comparison to the baseline appearance. Effectiveness is defined as change from baseline on both sides of the face using WAS at 48 Weeks after the first

Interventions

  • DEVICE Sculptra Aesthetic 8ml
  • DEVICE Sculptra Aesthetic 5ml

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2018-12-18
Est. Completion 2020-02-28
Phase NA
Galderma R&D

158 total trials

What the finished NCT03780244 record still lists

NCT03780244 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).

The record links to 0 conditions, and to 2 interventions - of which Sculptra Aesthetic 8ml is the first listed.

NCT03780244 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03780244 about?

NCT03780244 is a clinical study titled "Safety and Effectiveness of Sculptra Aesthetic for Correction of Nasolabial Folds.". This study has been designed to evaluate the safety of Sculptra Aesthetic as a single regimen for correction of Nasolabial Fold (NLF) contour deficiencies after changes in reconstitution and injection procedures compared to the approved label.

What is the current status of trial NCT03780244?

This trial is currently completed. It is a NA study. The enrollment target is 80 participants. The study started on 2018-12-18. Estimated completion is 2020-02-28.

What interventions are being tested in trial NCT03780244?

The interventions under investigation include: Sculptra Aesthetic 8ml (DEVICE), Sculptra Aesthetic 5ml (DEVICE).

Who is sponsoring clinical trial NCT03780244?

This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03780244's enrollment target sits among peer trials

80 994th of 2000 higher than 941 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03780244, the US trial registry maintained by the National Library of Medicine. NCT03780244 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.